{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:28:33Z","timestamp":1789450113436,"version":"build-2803163510"},"reference-count":67,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Infect Immun"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Analysis of the specificity of bactericidal antibodies in normal, convalescent, and postvaccination human sera is important in understanding human immunity to meningococcal infections and can aid in the design of an effective group B vaccine. A collection of human sera, including group C and group B convalescent-phase sera, normal sera with naturally occurring cross-reactive bactericidal activity, and some postvaccination sera, was analyzed to determine the specificity of cross-reactive bactericidal antibodies. Analysis of human sera using a bactericidal antibody depletion assay demonstrated that a significant portion of the bactericidal activity could be removed by purified lipopolysaccharide (LPS). LPS homologous to that expressed on the bactericidal test strain was most effective, but partial depletion by heterologous LPS suggested the presence of antibodies with various degrees of cross-reactivity. Binding of anti-L3,7 LPS bactericidal antibodies was affected by modification of the core structure, suggesting that these functional antibodies recognized epitopes consisting of both core structures and lacto-<jats:italic>N<\/jats:italic>-neotetraose (LNnT). When the target strain was grown with 5\u2032-cytidinemonophospho-<jats:italic>N<\/jats:italic>-acetylneuraminic acid (CMP-NANA) to increase LPS sialylation, convalescent-phase serum bactericidal titers were decreased by only 2- to 4-fold, and most remaining bactericidal activity was still depleted by LPS. Highly sialylated LPS was ineffective in depleting bactericidal antibodies. We conclude that natural infections caused by strains expressing L3,7 LPS induce persistent, protective bactericidal antibodies and appear to be directed against nonsialylated bacterial epitopes. Additionally, subsets of these bactericidal antibodies are cross-reactive, binding to several different LPS immunotypes, which is a useful characteristic for an effective group B meningococcal vaccine antigen.<\/jats:p>","DOI":"10.1128\/iai.05125-11","type":"journal-article","created":{"date-parts":[[2011,7,19]],"date-time":"2011-07-19T00:34:51Z","timestamp":1311035691000},"page":"4146-4156","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":17,"title":["Importance of Antibodies to Lipopolysaccharide in Natural and Vaccine-Induced Serum Bactericidal Activity against Neisseria meningitidis Group B"],"prefix":"10.1128","volume":"79","author":[{"given":"Deborah H.","family":"Schmiel","sequence":"first","affiliation":[{"name":"Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, Maryland 20910-7500"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth E.","family":"Moran","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, Maryland 20910-7500"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Keiser","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, Maryland 20910-7500"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda L.","family":"Brandt","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, Maryland 20910-7500"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendell D.","family":"Zollinger","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, 503 Robert Grant Ave., Silver Spring, Maryland 20910-7500"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1006\/mpat.1997.0143"},{"key":"e_1_3_3_3_2","volume-title":"Abstr. Sixth Ann. Conf. Vaccine Res.","author":"Babcock J.","year":"2003","unstructured":"BabcockJ.. 2003. Phase I study of meningococcal outer membrane protein-detoxified lipooligosaccharide vaccine in liposomes, poster P10. Abstr. Sixth Ann. Conf. Vaccine Res., Arlington, VA."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-004-0182-2"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2002.tb00633.x"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00398-10"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(94)00037-N"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/09680519010070060401"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(81)90281-5"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.carres.2008.08.026"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.06.011"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00483-3"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00216-9"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00882-06"},{"key":"e_1_3_3_15_2","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Fredriksen J. H.","year":"1991","unstructured":"FredriksenJ. H.. 1991. Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:67\u201379.(Discussion, 14:79-80.)","journal-title":"NIPH Ann."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/7.4.504"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)48372-X"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108235"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.129.6.1307"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/150.1.71"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.13.9716"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.11.4488-4493.1997"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.5.1873-1880.1993"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.09.041"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1139\/o80-018"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwi018"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/10408419891294216"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(78)90260-9"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.12.039"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.5.1566-1575.1994"},{"key":"e_1_3_3_31_2","first-page":"736","article-title":"A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines","volume":"18","author":"Koeberling O.","year":"2011","unstructured":"KoeberlingO.DelanyI.GranoffD. M.. 2011. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Infect. Immun. 18:736\u2013742.","journal-title":"Infect. Immun."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2005.00559.x"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/227680a0"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)52451-6"},{"key":"e_1_3_3_35_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1084\/jem.168.1.107","article-title":"Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes","volume":"168","author":"Mandrell R. E.","year":"1988","unstructured":"MandrellR. E.GriffissJ. M.MacherB. A.. 1988. Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens. Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize crossreacting antigens on LOS and human erythrocytes. J. Exp. Med. 168:107\u2013126.(Erratum, 168: 1517.)","journal-title":"J. Exp. Med."},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/jb.173.9.2823-2832.1991"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.16.2.471-475.1977"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)39105-7"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.100636"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.61.6.2390-2395.1993"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199510000-00008"},{"key":"e_1_3_3_42_2","volume-title":"Abstr. 14th Int. Pathog. Neisseria Conf.","author":"Pavliak V.","year":"2004","unstructured":"PavliakV.Fortuna-NevinM.MonteiroM.MasonK.ZhuD.. 2004. Neisseria meningitidis LOS conjugate vaccine against meningococcal disease, abstr. 8. Abstr. 14th Int. Pathog. Neisseria Conf., Milwaukee, WI."},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)85220-1"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00036-08"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6215(98)00012-3"},{"key":"e_1_3_3_46_2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.4049\/jimmunol.159.2.970","article-title":"Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide","volume":"159","author":"Reid R. R.","year":"1997","unstructured":"ReidR. R.. 1997. Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J. Immunol. 159:970\u2013975.","journal-title":"J. Immunol."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.1.113-119.1999"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.2174\/138920306778017972"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.16.1520"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.183.3.942-950.2001"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(82)90673-X"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.5.2454-2462.2002"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.59.3.843-851.1991"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004300050018"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.7.3223-3231.1998"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1515\/znb-1952-0303"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01108-08"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00411-07"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01915-06"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2007.01.002"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-148-6-1833"},{"key":"e_1_3_3_62_2","unstructured":"ZollingerW. D.. 17 November 1987. Process for the preparation of detoxified polysaccharide-outer membrane protein complexes and their use as antibacterial vaccines. U.S. patent 4 707 543."},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.05.006"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.40.1.257-264.1983"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.28.2.451-458.1980"},{"key":"e_1_3_3_66_2","volume-title":"Abstr. Front. Vaccine Res.","author":"Zollinger W. D.","year":"1991","unstructured":"ZollingerW. D.MoranE. E.RayJ.McClainB.. 1991. Phase I safety and immunogenicity study of a meningococcal outer membrane protein detoxified LPS vaccine. Abstr. Front. Vaccine Res., Helsinki, Finland."},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00255-09"},{"key":"e_1_3_3_68_2","unstructured":"ZollingerW. D.ShoemakerD.SaundersA. G.BrandtB. L.. 6 May 2003. Vaccine against gram negative bacteria. U.S. patent 6 558 677 B2."}],"container-title":["Infection and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.05125-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.05125-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T05:50:56Z","timestamp":1686203456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/IAI.05125-11"}},"subtitle":[],"editor":[{"given":"J. N.","family":"Weiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1128\/IAI.05125-11"],"URL":"https:\/\/doi.org\/10.1128\/iai.05125-11","relation":{},"ISSN":["0019-9567","1098-5522"],"issn-type":[{"value":"0019-9567","type":"print"},{"value":"1098-5522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"2011-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-07-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-09-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}